Stock CRMD CORMEDIX INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights CorMedix Inc.

Equities

CRMD

US21900C3088

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/07/2024 BST 		5-day change 1st Jan Change
4.28 USD -1.15% Intraday chart for CorMedix Inc. +0.71% +13.83%
05-28 CorMedix Shares Rise on Multiyear DefenCath Supply Deal MT
05-28 CorMedix Inc. Announces Commercial Agreement with Top Tier Dialysis Provider CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
CorMedix Shares Rise on Multiyear DefenCath Supply Deal
MT
CorMedix Inc. Announces Commercial Agreement with Top Tier Dialysis Provider
CI
CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
CorMedix's DefenCath Now Commercially Available For US Inpatient Use
MT
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)
CI
Sector Update: Health Care Stocks Decline Late Afternoon
MT
CorMedix to Supply to DefenCath to Florida-based Dialysis Organization
MT
CorMedix Inc. Announces Commercial Agreement with ARC Dialysis, LLC
CI
CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
CorMedix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Inflation Data -2-
DJ
CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath
CI
Cormedix Inc. Announces Commercial and Operational Updates
CI
CorMedix Inc. Announces Partnership with The Leapfrog Group
CI
CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients
CI
CorMedix's DefenCath Approved by US FDA; Shares Jump
MT
U.S. FDA approves CorMedix's antimicrobial drug
RE
CorMedix Q3 Net Loss Steady; Sees Cash Position Sufficient to Fund Operations for 12 Months
MT
CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
CorMedix Gets US Patent Covering Lead Product DefenCath
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRMD Stock
  4. News CorMedix Inc.
  5. Highlights